A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms IGUANA
- Sponsors Galapagos NV
- 13 Mar 2018 According to a MorphoSys media release, company plans to initiate this trial in second quarter of 2018.
- 20 Feb 2018 New trial record
- 17 Feb 2018 According to a MorphoSys media release, this trial is planned to be initiated in first half of 2018.